Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

A novel vascular homing peptide strategy to selectively enhance pulmonary drug efficacy in pulmonary arterial hypertension.

Toba M, Alzoubi A, O'Neill K, Abe K, Urakami T, Komatsu M, Alvarez D, Järvinen TA, Mann D, Ruoslahti E, McMurtry IF, Oka M.

Am J Pathol. 2014 Feb;184(2):369-75. doi: 10.1016/j.ajpath.2013.10.008. Epub 2014 Jan 6.

2.

Peptide-directed highly selective targeting of pulmonary arterial hypertension.

Urakami T, Järvinen TA, Toba M, Sawada J, Ambalavanan N, Mann D, McMurtry I, Oka M, Ruoslahti E, Komatsu M.

Am J Pathol. 2011 Jun;178(6):2489-95. doi: 10.1016/j.ajpath.2011.02.032. Epub 2011 May 6.

3.

Imatinib attenuates monocrotaline pulmonary hypertension and has potent vasodilator activity in pulmonary and systemic vascular beds in the rat.

Pankey EA, Thammasiboon S, Lasker GF, Baber S, Lasky JA, Kadowitz PJ.

Am J Physiol Heart Circ Physiol. 2013 Nov 1;305(9):H1288-96. doi: 10.1152/ajpheart.00329.2013. Epub 2013 Aug 30.

4.

Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats.

Abe K, Toba M, Alzoubi A, Koubsky K, Ito M, Ota H, Gairhe S, Gerthoffer WT, Fagan KA, McMurtry IF, Oka M.

Am J Respir Cell Mol Biol. 2011 Oct;45(4):804-8. doi: 10.1165/rcmb.2010-0371OC. Epub 2011 Mar 4.

5.

Peptide-micelle hybrids containing fasudil for targeted delivery to the pulmonary arteries and arterioles to treat pulmonary arterial hypertension.

Gupta N, Ibrahim HM, Ahsan F.

J Pharm Sci. 2014 Nov;103(11):3743-53. doi: 10.1002/jps.24193. Epub 2014 Sep 29.

6.

An evidence-based approach to the management of pulmonary arterial hypertension.

Archer SL, Michelakis ED.

Curr Opin Cardiol. 2006 Jul;21(4):385-92. Review.

PMID:
16755209
7.

Mechanism of the susceptibility of remodeled pulmonary vessels to drug-induced cell killing.

Ibrahim YF, Wong CM, Pavlickova L, Liu L, Trasar L, Bansal G, Suzuki YJ.

J Am Heart Assoc. 2014 Feb 26;3(1):e000520. doi: 10.1161/JAHA.113.000520.

8.

Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension.

Baliga RS, Zhao L, Madhani M, Lopez-Torondel B, Visintin C, Selwood D, Wilkins MR, MacAllister RJ, Hobbs AJ.

Am J Respir Crit Care Med. 2008 Oct 15;178(8):861-9. doi: 10.1164/rccm.200801-121OC. Epub 2008 Aug 8.

9.

Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension.

Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D, Wang SH, Modry D, Archer SL.

Circulation. 2003 Oct 28;108(17):2066-9. Epub 2003 Oct 20.

10.

Imatinib attenuates hypoxia-induced pulmonary arterial hypertension pathology via reduction in 5-hydroxytryptamine through inhibition of tryptophan hydroxylase 1 expression.

Ciuclan L, Hussey MJ, Burton V, Good R, Duggan N, Beach S, Jones P, Fox R, Clay I, Bonneau O, Konstantinova I, Pearce A, Rowlands DJ, Jarai G, Westwick J, MacLean MR, Thomas M.

Am J Respir Crit Care Med. 2013 Jan 1;187(1):78-89. doi: 10.1164/rccm.201206-1028OC. Epub 2012 Oct 18.

PMID:
23087024
11.

Heterogeneity in lung (18)FDG uptake in pulmonary arterial hypertension: potential of dynamic (18)FDG positron emission tomography with kinetic analysis as a bridging biomarker for pulmonary vascular remodeling targeted treatments.

Zhao L, Ashek A, Wang L, Fang W, Dabral S, Dubois O, Cupitt J, Pullamsetti SS, Cotroneo E, Jones H, Tomasi G, Nguyen QD, Aboagye EO, El-Bahrawy MA, Barnes G, Howard LS, Gibbs JS, Gsell W, He JG, Wilkins MR.

Circulation. 2013 Sep 10;128(11):1214-24. doi: 10.1161/CIRCULATIONAHA.113.004136. Epub 2013 Jul 30.

12.

Peptide-coated liposomal fasudil enhances site specific vasodilation in pulmonary arterial hypertension.

Nahar K, Absar S, Gupta N, Kotamraju VR, McMurtry IF, Oka M, Komatsu M, Nozik-Grayck E, Ahsan F.

Mol Pharm. 2014 Dec 1;11(12):4374-84. doi: 10.1021/mp500456k. Epub 2014 Nov 4.

13.

Temporal hemodynamic and histological progression in Sugen5416/hypoxia/normoxia-exposed pulmonary arterial hypertensive rats.

Toba M, Alzoubi A, O'Neill KD, Gairhe S, Matsumoto Y, Oshima K, Abe K, Oka M, McMurtry IF.

Am J Physiol Heart Circ Physiol. 2014 Jan 15;306(2):H243-50. doi: 10.1152/ajpheart.00728.2013. Epub 2013 Nov 15.

14.

Synergistic therapeutic effects of 2-methoxyestradiol with either sildenafil or bosentan on amelioration of monocrotaline-induced pulmonary hypertension and vascular remodeling.

Tofovic SP, Jones TJ, Bilan VP, Jackson EK, Petrusevska G.

J Cardiovasc Pharmacol. 2010 Nov;56(5):475-83. doi: 10.1097/FJC.0b013e3181f215e7.

PMID:
20881615
15.

A lymphocyte-dependent mode of action for imatinib mesylate in experimental pulmonary hypertension.

Ormiston ML, Deng Y, Rundle N, Bendjelloul F, Tsoporis JN, Parker TG, Stewart DJ, Courtman DW.

Am J Pathol. 2013 May;182(5):1541-51. doi: 10.1016/j.ajpath.2013.01.031. Epub 2013 Mar 19.

PMID:
23518411
16.

[Treatment with imatinib for refractory PAH].

Nakamura K, Akagi S, Sarashina T, Ogawa A, Matsubara H, Ito H.

Nihon Yakurigaku Zasshi. 2014 Apr;143(4):173-7. Review. Japanese. No abstract available.

PMID:
24717604
17.

Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension.

Gupta V, Gupta N, Shaik IH, Mehvar R, McMurtry IF, Oka M, Nozik-Grayck E, Komatsu M, Ahsan F.

J Control Release. 2013 Apr 28;167(2):189-99. doi: 10.1016/j.jconrel.2013.01.011. Epub 2013 Jan 23.

18.

Evaluation of imatinib mesylate in the treatment of pulmonary arterial hypertension.

Chhina MK, Nargues W, Grant GM, Nathan SD.

Future Cardiol. 2010 Jan;6(1):19-35. doi: 10.2217/fca.09.54. Review.

PMID:
20014985
19.

Delivery of imatinib-incorporated nanoparticles into lungs suppresses the development of monocrotaline-induced pulmonary arterial hypertension.

Akagi S, Nakamura K, Miura D, Saito Y, Matsubara H, Ogawa A, Matoba T, Egashira K, Ito H.

Int Heart J. 2015 May 13;56(3):354-9. doi: 10.1536/ihj.14-338. Epub 2015 Apr 23.

Supplemental Content

Support Center